AOD-9604 is used in research to investigate fat metabolism, energy balance, and adipose-tissue signaling in controlled laboratory models
The standard dose escalation protocol Based on the Phase 2 clinical trial data published in the New England Journal of Medicine, the typical retatrutide dose schedule follows a pattern like this: During the starting phase, a single 10mg vial reconstituted with 2mL of bacteriostatic water can last up to 10 weeks at a 1mg weekly dose
Research into this peptide has shown some patients experiencing significant weight loss thanks to this peptide
Its regulation of angiogenesis and inflammatory pathways contributes to improved outcomes in burn, incision, and chronic wound studies
Today, AOD-9604 remains a topic of scientific interest, not as an approved therapy, but as a case study in how translational challenges can derail promising preclinical results